THE SAFETY AND TOLERABILITY OF MULTIPLE DOSE ADMINISTRATION OF CSL112, AN INTRAVENOUS FORMULATION OF PLASMA-DERIVED APOA-I, AMONG SUBJECTS WITH MODERATE RENAL IMPAIRMENT AFTER ACUTE MYOCARDIAL INFARCTION

C. Michael Gibson,Megan Yee,Yazan Daaboul,Serge Korjian,Ali Poyan Mehr,Mathieu Kerneis,Pierluigi Tricoci,John Alexander,John Kastelein,Roxana Mehran,Christoph Bode,Basil Lewis,Ravindra Mehta,Danielle Duffy,John Feaster,Majdi Halabi,Dominick J. Angiolillo,Daniel Duerschmied,Ton Oude Ophius,Bela Merkely

THE SAFETY AND TOLERABILITY OF MULTIPLE DOSE ADMINISTRATION OF CSL112, AN INTRAVENOUS FORMULATION OF PLASMA-DERIVED APOA-I, AMONG SUBJECTS WITH MODERATE RENAL IMPAIRMENT AFTER ACUTE MYOCARDIAL INFARCTION

2018

CSL112 is plasma-derived apolipoprotein A-I (apoA-I), currently in development for early reduction of cardiovascular risk after acute myocardial infarction (AMI). The AEGIS-I trial demonstrated renal and hepatic safety and elevations in cholesterol efflux with 4 weekly intravenous infusions of 2g or

Keywords:

Apolipoprotein B
Myocardial infarction
Diabetes mellitus
Cholesterol
Internal medicine
Intravenous Infusions
Tolerability
Medicine
Cardiology
plasma derived
multiple dose

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations